Immediate Hypersensitivity Reactions Differential Diagnoses

1. Gell PGH, Coombs RRA, eds. Clinical Aspects of Immunology. Oxford, England: Blackwell; 1963.

2. Ariza A, Fernandez TD, Doña I, Aranda A, Blanca-Lopez N, Melendez L, et al. Basophil activation after nonsteroidal anti-inflammatory drugs stimulation in patients with immediate hypersensitivity reactions to these drugs. Cytometry A. 2014 Jan 17. [QxMD MEDLINE Link].

3. Sell S, Rich RR, Fleisher TA, et al, eds. Clinical Immunology: Principles and Practice. 1st ed. St. Louis, Mo: Mosby-Year Book; 1996. 449-77.

4. Lawlor GJ, Fischer TJ, Adelman DC, eds. Manual of Allergy and Immunology. 3rd ed. Philadelphia, Pa: Lippincott-Raven; 1995.

5. Wu LC, Zarrin AA. The production and regulation of IgE by the immune system. Nat Rev Immunol. 2014 Mar 14. [QxMD MEDLINE Link].

6. Nimmagadda SR, Evans R 3rd. Allergy: etiology and epidemiology. Pediatr Rev. 1999 Apr. 20(4):111-5; quiz 116. [QxMD MEDLINE Link].

7. von Bubnoff D, Geiger E, Bieber T. Antigen-presenting cells in allergy. J Allergy Clin Immunol. 2001 Sep. 108(3):329-39. [QxMD MEDLINE Link].

8. Adkinson Jr NF, Bochner BS, Busse WW, Holgate ST, Lemanske Jr RF, Simons FER. Middleton’s Allergy: Principles and Practice. 7th. PA: Mosby Elsevier; 2009.

9. Middleton E, Reed C, Ellis E, eds. Allergy: Principles and Practice. 5th ed. St. Louis, Mo: Mosby-Year Book; 1998.

10. Paul WE. Fundamental Immunology. 2nd ed. Columbus, Ohio: Primis Custom Publishing; 1999.

11. Fukuoka Y, Xia HZ, Sanchez-Muñoz LB, Dellinger AL, Escribano L, Schwartz LB. Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5. J Immunol. 2008 May 1. 180(9):6307-16. [QxMD MEDLINE Link]. [Full Text].

12. Brunnée T, Reddigari SR, Shibayama Y, Kaplan AP, Silverberg M. Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy. 1997 Jun. 27(6):653-63. [QxMD MEDLINE Link].

13. Noga O, Brunnée T, Schäper C, Kunkel G. Heparin, derived from the mast cells of human lungs is responsible for the generation of kinins in allergic reactions due to the activation of the contact system. Int Arch Allergy Immunol. 1999 Dec. 120(4):310-6. [QxMD MEDLINE Link].

14. Pearlman DS. Pathophysiology of the inflammatory response. J Allergy Clin Immunol. 1999 Oct. 104(4 Pt 1):S132-7. [QxMD MEDLINE Link].

15. Schoenwetter WF. Allergic rhinitis: epidemiology and natural history. Allergy Asthma Proc. 2000 Jan-Feb. 21(1):1-6. [QxMD MEDLINE Link].

16. Akinbami LJ, Moorman, JE, Bailey C, et al. Trends in Asthma Prevalence, Health Care Use and Mortality: United States, 2001-2010. Hyattsville, Md: National Center for Health Statistics; 2012. 94: 1-6.

17. Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010 Sep. 126(3):477-80.e1-42. [QxMD MEDLINE Link].

18. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004 May. 59(5):469-78. [QxMD MEDLINE Link].

19. Janson C, Anto J, Burney P, et al. The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. Eur Respir J. 2001 Sep. 18(3):598-611. [QxMD MEDLINE Link].

20. Asher MI, Keil U, Anderson HR, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J. 1995 Mar. 8(3):483-91. [QxMD MEDLINE Link].

21. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006 Aug 26. 368(9537):733-43. [QxMD MEDLINE Link].

22. Lawson JA, Senthilselvan A. Asthma epidemiology: has the crisis passed?. Curr Opin Pulm Med. 2005 Jan. 11(1):79-84. [QxMD MEDLINE Link].

23. Keller MB, Lowenstein SR. Epidemiology of asthma. Semin Respir Crit Care Med. 2002 Aug. 23(4):317-29. [QxMD MEDLINE Link].

24. Gupta R, Sheikh A, Strachan DP, Anderson HR. Time trends in allergic disorders in the UK. Thorax. 2007 Jan. 62(1):91-6. [QxMD MEDLINE Link].

25. Busse WW. Mechanisms and advances in allergic diseases. J Allergy Clin Immunol. 2000 Jun. 105(6 Pt 2):S593-8. [QxMD MEDLINE Link].

26. Lasley MV. Allergic disease prevention and risk factor identification. Immunol Allergy Clin North Am. 1999. 19:149-59.

27. von Mutius E, Braun-Fahrländer C, Schierl R, Riedler J, Ehlermann S, Maisch S. Exposure to endotoxin or other bacterial components might protect against the development of atopy. Clin Exp Allergy. 2000 Sep. 30(9):1230-4. [QxMD MEDLINE Link].

28. Akinbami LJ, Moorman JE, Bailey C, Zahran HS, King M, Johnson CA, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. NCHS Data Brief. 2012 May. 1-8. [QxMD MEDLINE Link].

29. Asthma in the US. Available at http://www.cdc.gov/vitalsigns/asthma/. Accessed: September 3, 2014.

30. Guinnepain MT, Eloit C, Raffard M, Brunet-Moret MJ, Rassemont R, Laurent J. Exercise-induced anaphylaxis: useful screening of food sensitization. Ann Allergy Asthma Immunol. 1996 Dec. 77(6):491-6. [QxMD MEDLINE Link].

31. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007 Nov. 120(5 Suppl):S94-138. [QxMD MEDLINE Link].

32. Rosenwasser LJ, Klemm DJ, Dresback JK, Inamura H, Mascali JJ, Klinnert M. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy. 1995 Nov. 25 Suppl 2:74-8; discussion 95-6. [QxMD MEDLINE Link].

33. Stock P, DeKruyff RH, Umetsu DT. Inhibition of the allergic response by regulatory T cells. Curr Opin Allergy Clin Immunol. 2006 Feb. 6(1):12-6. [QxMD MEDLINE Link].

34. Cox L. Overview of serological-specific IgE antibody testing in children. Curr Allergy Asthma Rep. 2011 Dec. 11(6):447-53. [QxMD MEDLINE Link].

35. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003 Jun. 111(6):1255-61. [QxMD MEDLINE Link].

36. Label: GRASTEK- phleum pratense pollen tablet. Available at http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1d7f3e56-c233-47a4-9bcd-80098ffff47d. Accessed: September 8, 2014.

37. Label: RAGWITEK- ambrosia artemisiifolia pollen tablet. Available at http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=986abfaf-67fc-47fb-8c86-d9f9cce6fa8b. Accessed: September 8, 2014.

38. ORALAIR [package insert]. Available at [Full Text].

39. Ruffin CG, Busch BE. Omalizumab: a recombinant humanized anti-IgE antibody for allergic asthma. Am J Health Syst Pharm. 2004 Jul 15. 61(14):1449-59. [QxMD MEDLINE Link].

40. Davis LA. Omalizumab: a novel therapy for allergic asthma. Ann Pharmacother. 2004 Jul-Aug. 38(7-8):1236-42. [QxMD MEDLINE Link].

41. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001 Aug. 108(2):184-90. [QxMD MEDLINE Link].

42. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014 May. 133(5):1270-7. [QxMD MEDLINE Link].

43. Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep. 2006 Jul. 6(4):270-4. [QxMD MEDLINE Link].

44. Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol. 2005. 6(2):65-77. [QxMD MEDLINE Link].

45. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol. 2001 Nov. 108(5):871-3. [QxMD MEDLINE Link].

46. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol. 1998 Jan. 101(1 Pt 1):33-7. [QxMD MEDLINE Link].

47. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006 Jan. 129(1):15-26. [QxMD MEDLINE Link].

48. Loymans RJ, Gemperli A, Cohen J, Rubinstein SM, Sterk PJ, Reddel HK, et al. Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. BMJ. 2014 May 13. 348:g3009. [QxMD MEDLINE Link]. [Full Text].

49. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 Mar 7. 368(10):924-35. [QxMD MEDLINE Link].

50. Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003 Mar 13. 348(11):986-93. [QxMD MEDLINE Link].

51. Schatz M, Zeiger RS. Allergic disease during pregnancy: current treatment options. J Resp Dis. 1998. 19:834-42.

52. Busse WW, Coffman RL, Gelfand EW, et al. Mechanisms of persistent airway inflammation in asthma. A role for T cells and T-cell products. Am J Respir Crit Care Med. 1995 Jul. 152(1):388-93. [QxMD MEDLINE Link].

53. Centers for Disease Control and Prevention (CDC). Compressed Mortality File, CDC WONDER. Atlanta, Ga: CDC; 2006.

54. Cockcroft D, Davis B. Direct and indirect challenges in the clinical assessment of asthma. Ann Allergy Asthma Immunol. 2009 Nov. 103(5):363-9; quiz 369-72, 400. [QxMD MEDLINE Link].

55. Grant EN, Lyttle CS, Weiss KB. The relation of socioeconomic factors and racial/ethnic differences in US asthma mortality. Am J Public Health. 2000 Dec. 90(12):1923-5. [QxMD MEDLINE Link].

56. Haahtela T, Lindholm H, Björkstén F, Koskenvuo K, Laitinen LA. Prevalence of asthma in Finnish young men. BMJ. 1990 Aug 4. 301(6746):266-8. [QxMD MEDLINE Link].

57. Johansson-Lindbom B, Borrebaeck CA. Germinal center B cells constitute a predominant physiological source of IL-4: implication for Th2 development in vivo. J Immunol. 2002 Apr 1. 168(7):3165-72. [QxMD MEDLINE Link].

58. Keeley DJ, Neill P, Gallivan S. Comparison of the prevalence of reversible airways obstruction in rural and urban Zimbabwean children. Thorax. 1991 Aug. 46(8):549-53. [QxMD MEDLINE Link].

59. Kepil Özdemir S, Yilmaz I, Aydin Ö, Büyüköztürk S, Gelincik A, Demirtürk M, et al. Immediate-type hypersensitivity reactions to proton pump inhibitors: usefulness of skin tests in the diagnosis and assessment of cross-reactivity. Allergy. 2013 Aug. 68(8):1008-14. [QxMD MEDLINE Link].

60. Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest. 2001 Dec. 108(12):1865-73. [QxMD MEDLINE Link].

61. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009 Aug 27. 361(9):888-98. [QxMD MEDLINE Link].

62. Nelson HS. Immunotherapy for inhalant allergens. Adkinson NF, Bochner BS, Busse WW, Holgate ST, Lemanske RF, Simons FE. Middleton's Allergy Principles and Practice. 7th ed. Philadelphia, Pa: Elsevier; 2009. Vol 2: 1672-3.

63. Novalbos A, Sastre J, Cuesta J, De Las Heras M, Lluch-Bernal M, Bombín C. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clin Exp Allergy. 2001 Mar. 31(3):438-43. [QxMD MEDLINE Link].

64. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med. 2001 Oct 15. 164(8 Pt 2):S1-5. [QxMD MEDLINE Link].

65. Strachan DP, Wong HJ, Spector TD. Concordance and interrelationship of atopic diseases and markers of allergic sensitization among adult female twins. J Allergy Clin Immunol. 2001 Dec. 108(6):901-7. [QxMD MEDLINE Link].

66. Weber RW. Immunotherapy with allergens. JAMA. 1997 Dec 10. 278(22):1881-7. [QxMD MEDLINE Link].

67. Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy. 2002 Oct. 32(10):1504-9. [QxMD MEDLINE Link].

68. Xystrakis E, Boswell SE, Hawrylowicz CM. T regulatory cells and the control of allergic disease. Expert Opin Biol Ther. 2006 Feb. 6(2):121-33. [QxMD MEDLINE Link].

69. Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet. 2019 Aug 3. 394 (10196):407-418. [QxMD MEDLINE Link].

70. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012 Mar 19. 12:204. [QxMD MEDLINE Link].

71. Anandan C, Nurmatov U, van Schayck OC, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy. 2010 Feb. 65 (2):152-67. [QxMD MEDLINE Link].

72. Patel A, Bahna SL. Hypersensitivities to sesame and other common edible seeds. Allergy. 2016 Oct. 71 (10):1405-13. [QxMD MEDLINE Link].

73. Graft DF. Insect sting allergy. Med Clin North Am. 2006 Jan. 90 (1):211-32. [QxMD MEDLINE Link].

74. Moffitt JE, Golden DB, Reisman RE, Lee R, Nicklas R, Freeman T, et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol. 2004 Oct. 114 (4):869-86. [QxMD MEDLINE Link].

75. Shakir EM, Cheung DS, Grayson MH. Mechanisms of immunotherapy: a historical perspective. Ann Allergy Asthma Immunol. 2010 Nov. 105 (5):340-7; quiz 348, 368. [QxMD MEDLINE Link].

76. Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016 Dec. 138 (6):1631-1638. [QxMD MEDLINE Link].

77. Shakir EM, Cheung DS, Grayson MH. Mechanisms of immunotherapy: a historical perspective. Ann Allergy Asthma Immunol. 2010 Nov. 105 (5):340-7; quiz 348, 368. [QxMD MEDLINE Link].

78. Porebski G, Kwiecien K, Pawica M, Kwitniewski M. Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) in Drug Hypersensitivity Reactions. Front Immunol. 2018. 9:3027. [QxMD MEDLINE Link].

79. Han Y, Chen Y, Liu X, Zhang J, Su H, Wen H, et al. Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2017 Sep. 140 (3):888-891.e6. [QxMD MEDLINE Link].

80. Contopoulos-Ioannidis DG, Kouri IN, Ioannidis JP. Genetic predisposition to asthma and atopy. Respiration. 2007. 74 (1):8-12. [QxMD MEDLINE Link].

81. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006 Apr. 38 (4):441-6. [QxMD MEDLINE Link].

82. Giubergia V, Gravina LP, Castaños C, Chertkoff L, Grenoville M. Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children. Pediatr Pulmonol. 2008 May. 43 (5):421-5. [QxMD MEDLINE Link].

83. Ullemar V, Magnusson PK, Lundholm C, Zettergren A, Melén E, Lichtenstein P, et al. Heritability and confirmation of genetic association studies for childhood asthma in twins. Allergy. 2016 Feb. 71 (2):230-8. [QxMD MEDLINE Link].

84. Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015 Feb 26. 372 (9):803-13. [QxMD MEDLINE Link].

85. Du Toit G, Sayre PH, Roberts G, Sever ML, Lawson K, Bahnson HT, et al. Effect of Avoidance on Peanut Allergy after Early Peanut Consumption. N Engl J Med. 2016 Apr 14. 374 (15):1435-43. [QxMD MEDLINE Link].

86. Joint Task Force on Practice Parameters., American Academy of Allergy, Asthma and Immunology., American College of Allergy, Asthma and Immunology., Joint Council of Allergy, et al. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010 Oct. 105 (4):259-273. [QxMD MEDLINE Link].

87. Peter Bradding and Hirohisa Saito. Biology of Mast Cells and Their Mediators. Middleton's Allergy: Principles and Practice: Eighth Edition. 8th.

88. Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United States, 2005-2009. Natl Health Stat Report. 2011 Jan 12. 1-14. [QxMD MEDLINE Link].

89. Zahran HS, Bailey CM, Damon SA, Garbe PL, Breysse PN. Vital Signs: Asthma in Children - United States, 2001-2016. MMWR Morb Mortal Wkly Rep. 2018 Feb 9. 67 (5):149-155. [QxMD MEDLINE Link].

90. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J. 1996 Apr. 9 (4):687-95. [QxMD MEDLINE Link].

91. Prescott SL, Pawankar R, Allen KJ, Campbell DE, Sinn JKh, Fiocchi A, et al. A global survey of changing patterns of food allergy burden in children. World Allergy Organ J. 2013 Dec 4. 6 (1):21. [QxMD MEDLINE Link].

92. Eric Schauberger, Jocelyn M Biagini Myers. Epidemiology of Asthma and Allergic Diseases. Middleton's: Principles and Practice. 9th. December 2019.

93. Zilberstein J, McCurdy MT, Winters ME. Anaphylaxis. J Emerg Med. 2014 Aug. 47 (2):182-7. [QxMD MEDLINE Link].

94. AsthmaStats. https://www.cdc.gov/asthma/asthma_stats/documents/AsthmStat_Mortality_2001-2016-H.pdf.

95. Asthma. https://www.cdc.gov/nchs/fastats/asthma.htm. Accessed: 6/23/2020.

96. Allergies and Hay Fever. https://www.cdc.gov/nchs/fastats/allergies.htm. 6/23/2020;

97. Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019 Jun. 53 (6):[QxMD MEDLINE Link].

98. FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. Available at https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market. 4/1/2020; Accessed: 7/24/2020.

Becky Buelow, MD, MS Instructor, Section of Allergy and Clinical Immunology, Department of Pediatrics, Medical College of Wisconsin

Becky Buelow, MD, MS is a member of the following medical societies: Alpha Omega Alpha, American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American College of Allergy, Asthma and Immunology, Clinical Immunology Society, Wisconsin Allergy Society

Disclosure: Nothing to disclose.

John M Routes, MD Chief, Section of Allergy and Clinical Immunology, Department of Pediatrics, Children's Hospital of Wisconsin; Professor of Pediatrics, Medicine, Microbiology, and Immunology, Medical College of Wisconsin

John M Routes, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Allergy, Asthma and Immunology, American Society for Microbiology, American Society for Virology, Clinical Immunology Society, Federation of American Societies for Experimental Biology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Michael R Simon, MD, MA Clinical Professor Emeritus, Departments of Internal Medicine and Pediatrics, Wayne State University School of Medicine; Professor, Department of Internal Medicine, Oakland University William Beaumont University School of Medicine; Adjunct Staff, Division of Allergy and Immunology, Department of Internal Medicine, William Beaumont Hospital

Michael R Simon, MD, MA is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American College of Allergy, Asthma and Immunology, American College of Physicians, American Federation for Medical Research, Michigan Allergy and Asthma Society, Michigan State Medical Society, Royal College of Physicians and Surgeons of Canada, Society for Experimental Biology and Medicine

Disclosure: Have a 5% or greater equity interest in: Secretory IgA, Inc. ; siRNAx, Inc.<br/>Received income in an amount equal to or greater than $250 from: siRNAx, Inc.

Michael A Kaliner, MD Clinical Professor of Medicine, George Washington University School of Medicine; Medical Director, Institute for Asthma and Allergy

Michael A Kaliner, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Allergy, Asthma and Immunology, American Society for Clinical Investigation, American Thoracic Society, Association of American Physicians

Disclosure: Nothing to disclose.

Miriam K Anand, MD, FAAAAI, FACAAI Consulting Staff, Department of Allergy/Immunology, Allergy Associates and Lab, Ltd; Clinical Assistant Professor, Midwestern School of Osteopathic Medicine

Miriam K Anand, MD, FAAAAI, FACAAI is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American College of Allergy, Asthma and Immunology, American College of Physicians-American Society of Internal Medicine, and American Medical Association

Disclosure: TEVA pharmaceuticals Honoraria Speaking and teaching

• Print this section
• Print the entire contents of
• Print the entire contents of article